Ocugen, Inc. (NASDAQ: OCGN) shares are trading higher amid heightened interest in the stock from retail traders on social media.
According to SwaggyStocks, Ocugen was the fifth most mentioned stock on Reddit’s r/wallstreetbets.
Traders also circulated a recent release from the Australian Government mentioning recognition of Bharat Biotech’s COVAXIN. NOTE: Ocugen is a partner on COVAXIN.
Ocugen’s average session volume is 21.45 million over a 100-day period. At publication time, Monday’s trading volume had already exceeded 83.62 million, according to data from Benzinga Pro.
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.
Ocugen’s stock was trading about 16% higher at $13.73 per share on Monday at the time of publication. The stock has a 52-week high of $18.77 and a 52-week low of $0.25.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
